Orca Bio Strengthens Leadership Team with Appointment of Steve Gavel as Chief Commercial Officer

Orca Bio has announced the appointment of Steve Gavel as Chief Commercial Officer, a move that underscores the company's preparation for the potential commercial launch of its lead investigational allogeneic T-cell immunotherapy, Orca-T®. Gavel, with over 30 years of experience in the biotechnology and pharmaceutical sectors, brings a wealth of knowledge in the commercialization of cell and gene therapies. His previous role at Legend Biotech involved leading the global launch of Carvykti®, a treatment for relapsed or refractory multiple myeloma, showcasing his capability in steering commercial strategies for groundbreaking therapies.

In addition to Gavel's appointment, Orca Bio has welcomed Allison Frisbee as Senior Vice President, Legal. Frisbee's extensive experience in the life science industry, particularly in navigating complex legal and regulatory landscapes, will be invaluable as Orca Bio advances its mission to transform the therapeutic landscape for patients with high-risk blood cancers. These strategic hires reflect Orca Bio's commitment to not only advancing its high-precision cell therapies but also ensuring a robust framework for their commercialization and compliance.

The implications of these appointments are significant for the biotechnology industry and patients alike. With Gavel at the helm of commercial operations, Orca Bio is poised to effectively bring Orca-T® to market, offering hope to patients with conditions such as acute myeloid leukemia and myelodysplastic syndrome. Frisbee's leadership in legal and compliance matters further solidifies the company's foundation, ensuring that its innovative therapies reach patients in a manner that is both ethical and compliant with regulatory standards. Together, these developments signal Orca Bio's readiness to enter a new phase of growth and its unwavering commitment to improving patient outcomes through high-precision cell therapy.